Phase I/II COMBI-i . Phase 3 negative. The 40% CR rate in early phase disappeared. Notable that KN-022 & independent analysis of IMspire150 also (-). BRAF-MEK-PD1/L1 is import for high volume dz or brain mets but no broad role for #melanoma.
Reinhard Dummer & cols describe the clinical activity and biomarker analysis from the COMBI-i trial evaluating PD-1, BRAF and MEK inhibition in metastatic #Melanoma patients―high response rates and molecular correlates of long-term benefit #NMEDclinical